

'ELLAONE PREGNANCY REGISTRY' WEBSITE TERMS OF USE AND CONTACT INFORMATION

By continuing to browse the site <http://www.hra-pregnancy-registry.com/> or the site <http://www.hra-pregnancy-registry.fr> (hereafter both called 'the Site') you are unconditionally agreeing to the following terms of use. The version of these terms of use currently online will alone be binding throughout your use of the Site, until replaced by a new version.

Article 1 - Legal information about the Site

The legal information about the Site is as follows:

- **Publisher:** Laboratoire HRA Pharma (hereafter 'HRA Pharma'), a simplified joint-stock company with registered capital of 84,778,228.00 euros, having its registered office at 200, avenue de Paris, 92320 Châtillon, Companies' Register of Nanterre No 420 792 582, represented by its chairperson, the company HERA, a simplified joint-stock company, having its registered office at 200, avenue de Paris, 92320 Châtillon, Companies' Register of Nanterre No 814 697 892, with legal representative Mr David Wright
Telephone number: +33 (0)1 40 33 11 30
Email: contact@hra-pharma.com
- **Publication Director:** Mr David Wright
- **Site design and creation:** SAS InAdvans, 8 rue de l'arcade, 75008 Paris, <https://www.inadvans.com>, supplier of the secure collection solution for health care data and of the design of the Site
- **Hosting company:** A.T.E., Parc des Moulins, 21, avenue de la Créativité, 59650 Villeneuve d'Ascq, <https://www.ate.info>, authorised health care data host in accordance with the Public Health Code.

Article 2 – Purpose of the Site and relevant public

HRA Pharma is a pharmaceutical company (authorisation issued by the Agence Nationale de Sécurité du Médicament et des Produits de Santé (French medicines and health care products regulator), 143-147, Bd Anatole France 93285 Saint-Denis Cedex) and is the holder of the European marketing authorisation for the medicinal product ellaOne.

The purpose of the Site is to create a registry of medical data on pregnancies exposed to ellaOne (hereafter 'the Registry'). The Registry is created in agreement with national and international medicines agencies as part of pharmacovigilance for the medicinal product ellaOne.

Participation by the public for which the questionnaire in the Registry is intended, both the health care professionals and any women whose pregnancies have been exposed to the medicinal product ellaOne, is optional.

A failure to take part or to provide a response does not entail any consequences for the public concerned.

Given the importance of the Registry and of the information provided to it through the questionnaire in terms of public health care and pharmacovigilance, each declarant wishing to contribute to the Registry ('Declarant' or 'Declarants') undertakes when using the Site to provide information that is truthful, accurate, honest and not misleading.

The Site is not in any way a substitute for medical consultation, the establishment of a diagnosis or the implementation of therapeutic action of any kind. If she is a patient, the Declarant must speak to competent health care professionals in relation to her care.

HRA Pharma may need to ask for additional information from Declarants if they are patients, while respecting the anonymisation of their personal data, if and only if this becomes

necessary. If she is a patient, the Declarant therefore agrees to receive any additional questions that might be sent by the HRA Pharma Pharmacovigilance department.

There is no obligation to respond and a failure to respond does not entail any consequences for the Declarant concerned.

Article 5 - Ownership of the Site

The Site and all elements reproduced or used on the Site are protected by the applicable intellectual property laws.

They are the full and entire property of HRA Pharma or its partners. Any reproduction, representation, use or adaptation, in any form whatsoever, of all or part of these elements, including computer applications, without the prior written consent of HRA Pharma, is strictly prohibited. The fact that HRA Pharma does not initiate proceedings upon becoming aware of these unauthorised uses does not constitute acceptance of such uses and waiver of prosecution.

Any use not expressly authorised by HRA Pharma and/or InAdvans under these terms of use is unlawful pursuant to the provisions of the Intellectual Property Code.

Article 4 - Management of the Site

To ensure the proper management of the Site, HRA Pharma may at any time:

- suspend, interrupt or limit access to all or part of the Site and make all or part of it accessible only to a specific category of internet users;
- delete any information that could disrupt the normal operation of the Site or that contravenes national or international laws;
- suspend access to the Site to carry out updates.

Article 5 - Liability

HRA Pharma cannot be held liable in the event of a failure, breakdown, difficulty or interruption of operation preventing access to the Site or one of its functionalities.

The hardware you use to connect to the Site is subject to your entire liability. You must take all appropriate steps to protect your hardware and your own data, in particular from viral attacks over the internet.

HRA Pharma cannot be held liable in the event of legal proceedings against you:

- as a result of the use of the Site or any service accessible via the internet;
- as a result of your failure to comply with these terms of use.

HRA Pharma is not liable for any damage caused to you, third parties and/or your equipment as a result of your connection to or use of the Site and you waive any action against HRA Pharma as a result.

If HRA Pharma were to be the subject of amicable or legal proceedings as a result of your use of the Site, HRA Pharma may require that you stand surety for any sums for which it may be liable in connection with such proceedings.

Article 6 - Hypertext links

The creation, by the user of the Site, of any hypertext links to all or part of the Site is strictly prohibited, except with the prior written consent of HRA Pharma, requested by email from the following address: pharmacovigilance@hra-pharma.com

Article 7 – Cookies and protection of personal data

The protection of the personal data of patients and health care professionals completing the Registry is covered by legal information contained in the Personal Data Protection Policy available from the Site in accordance with Regulation (EU) No 2016/679 of 27 April 2016.

Article 8 - Applicable law

These terms of use for the Site are governed by French law and subject to the jurisdiction of the courts of Nanterre, subject to a specific attribution of jurisdiction deriving from a text of a specific law or regulation.

Article 9 - Contact us

For any questions about this Site or the Registry, please contact HRA Pharma at the following address: pharmacovigilance@hra-pharma.com or HRA Pharma, Pharmacovigilance Department, at the address of the registered office stated in these terms of use.

Last updated 8 February 2019